Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more


Friday 28 November 2014

HarvoniĀ®, a fixed-dose combination of ledipasvir (an HCV NS5A inhibitor) and sofosbuvir (an HCV nucleotide analog NS5B polymerase inhibitor, has been recently approved by the FDA and is awaiting marketing authorisation in Europe. Interactions between ledipasvir/sofosbuvir and comedications have been added to the web, app and printed versions of the charts.

Pharmacokinetic information for ledipasvir can be found in the investigational drug fact sheet (accessed via the Interaction Charts drop down menu). A PK fact sheet will be prepared once a European Summary of Characteristics is available for the ledipasvir/sofosbuvir combination.

Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017 building_better_healthcare_awards_2016